Syncom Formulations (India) Ltd Share Price Today - Syncom Formulations (India) Ltd Stock Price Live NSE/BSE

Syncom Formulations (India) Ltd

NSE: SYNCOMF BSE: 524470

₹13.24

(-2.58%)

Thu, 19 Feb 2026, 01:00 pm

MTF 5xInvest in Syncom Formulations (India) Ltd with 5x Leverage Buy with MTF

Market Cap12.88B

PE Ratio18.05

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Syncom Formulations (India) Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
1280.28
Net Profit
49.43
P/B
4.52
Sector P/E
31.95
P/E
31.04
EV/EBITDA
21.60
Debt/Equity (Industry)
0.25
Interest Cover (Industry)
12.50
ROCE (Industry)
15.30
RONW (Industry)
13.47
ROE
15.68
ROCE
18.54
Debt/Equity
0.12
EPS (TTM)
0.73
Dividend Yield
0
Book Value
4.03
Interest Cover
63.39

Analysis

all

Pros

Syncom Formulations (India) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Syncom Formulations (India) is profitable, therefore cash runway is not a concern.
Syncom Formulations (India) is profitable, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (98.3%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 9.3x debt.

Cons

Unable to calculate sustainability of dividends as Syncom Formulations (India) has not reported any payouts.
Unable to evaluate Syncom Formulations (India)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Syncom Formulations (India)'s dividend against the top 25% market benchmark as the company has not reported any payouts.
The level of debt compared to net worth has increased over the past 5 years (5.5% vs 6.3% today).
High level of physical assets or inventory.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	50.57	50.57	50.57	50.57	50.57
FII	0.26	0.10	0.41	0.11	0.13
DII	0.00	0.00	0.00	0.00	0.00
Public	49.17	49.33	49.02	49.32	49.30
Government	0	0	0	0	0

Technical Analysis

RSI

44.04

MACD

0.04

50 DMA

13.71

200 DMA

16.78

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	19.20	16.15	14.56	13.10	11.51	10.05	7.00
Fibonacci	16.15	14.99	14.27	13.10	11.94	11.22	10.05
Camarilla	13.80	13.52	13.24	13.10	12.68	12.40	12.12

Pivots Level: Classic

+6.10

19.20

+3.05

16.15

+1.45

14.56

13.10

Pivot Point

LTP: 13.11

-1.60

11.51

-3.05

10.05

-6.10

7.00

Moving Average

SMAEMA

Period

Value

10-EMA
13.62
20-EMA
13.56
30-EMA
13.60
50-EMA
13.90
100-EMA
14.78
200-EMA
15.86

Announcement Date	Purpose	Action	Ex Date
12 Feb 2026	board-meetings	Quarterly Results
11 Aug 2025	agm
19 Sept 2024	agm
14 Aug 2023	agm
13 Aug 2022	agm
13 Aug 2022	dividend	₹0.03 Dividend /Share	13 Sept 2022
27 Aug 2021	agm
18 Dec 2020	egm
14 Aug 2020	agm
30 May 2017	dividend	₹0.02 Dividend /Share	23 Sept 2017

Syncom Formulations (India) Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Cipla Ltd

Divis Laboratories Ltd

Syncom Formulations (India) Ltd About

Syncom Formulations (India) is a renowned name in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Currently Syncom manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1988

Headquarters

CEO

ANKIT KEDARMAL BANKDA

Employees

Contact

Website

http://www.syncomformulations.com

finance@sfil.in; sfil87@syncomformulations.com

Phone

91-22-30887744

Location

7 Niraj Indl Estate Andheri(E), Off Mahakali Caves Rd, Mumbai, Maharashtra, 400093

Year	History
2011	Mrs. Shikha Sethi was appointed as the Company Secretary of the Company.
2012	The Company incorporated a Wholly Owned Subsidiary Company named 'TRADE ZONE FZE' in the United Arab Emirates. Shri. Praveen Jindal was appointed as an Independent Director of the company.
2013	The Company announced a bonus in the ratio of 5:2. The Company split its face value from Rs 10 to Re. 1. The Company recommended a dividend of Rs. 0.60 per equity share of Rs. 10 each for the year 2012-13.
2014	The Company recommended a dividend of Rs. 0.02 per equity share of Re. 1 each for the year 2013-14. Smt. Rinki Bankda was appointed as an Additional Director of the Company.
2022	Syncom Formulations (India) Limited was awarded 'PRODUCT EXCELLENCE 2022' under the category of 'Pharma (Medium)'.

Client Name	Order Side	QTY	Avg Price	Date
HRTI PRIVATE LIMITED	Sell	8150466	25.14	09 Sept 2024
HRTI PRIVATE LIMITED	Buy	8536197	25.26	09 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	Buy	7106640	24.91	09 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	7106640	24.86	09 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	Buy	5329278	23.42	06 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	5329278	23.46	06 Sept 2024
HRTI PRIVATE LIMITED	Buy	4707047	23.37	06 Sept 2024
HRTI PRIVATE LIMITED	Sell	5094857	23.4	06 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	5331418	20.79	26 Aug 2024
HRTI PRIVATE LIMITED	Buy	7590091	20.78	26 Aug 2024

Syncom Formulations (India) Ltd News

Syncom Formulations Board Meet Set for Feb 12, 2026

Syncom Formulations (India) Limited has scheduled its board meeting for February 12, 2026, to consider and approve Q3FY26 unaudited financial results for quarter and nine months ended December 31, 2025.

04 Feb 2026

co actions results

Syncom Formulations Faces ₹1.42 Cr GST Demand

Syncom Formulations receives revised GST demand notice of ₹1.42 crores including penalty for ineligible input tax credits, plans to appeal the decision.

03 Jan 2026

stocks

Syncom Formulations Acquires Commercial Property in Mumbai for ₹51.70 Crores

Syncom Formulations (India) Limited has successfully acquired the entire 3rd Floor of TradeStar building on Andheri-Kurla Road, Mumbai, from HDFC Bank Ltd. The pharmaceutical company paid ₹51.70 crores as full and final consideration for this commercial property acquisition, which the company considers material in nature.

22 Nov 2025

corporate action

Syncom Formulations Reports Mixed Q2 Performance with Revenue Decline and Profit Drop

Syncom Formulations (India) Limited reported quarterly results for the period ended September 30, 2025. The company's revenue from operations decreased to Rs 12,143.51 lakhs compared to Rs 16,546.69 lakhs in the previous quarter. Net profit for the quarter stood at Rs 1,572.93 lakhs, down from Rs 1,695.00 lakhs in the prior quarter. For the half-year period, revenue reached Rs 28,690.20 lakhs versus Rs 18,735.68 lakhs in the corresponding previous period. The company operates in three business segments: Pharmaceuticals, Drugs & Formulations, Trading of Commodities, and Renting of Property. Basic earnings per share for the quarter was Rs 0.18 compared to Rs 0.21 in the previous quarter. The results were approved by the Board of Directors at their meeting held on November 12, 2025.

12 Nov 2025

earnings

Syncom Formulations Reports 49% Jump in Q2 Net Profit to 166 Million Rupees

Syncom Formulations (India) reported quarterly net profit of 166 million rupees compared to 111 million rupees in the same period last year. Revenue increased to 1.2 billion rupees from 1.02 billion rupees year-over-year. EBITDA rose to 184 million rupees from 122 million rupees, while EBITDA margin improved to 15.12% from 11.89% in the previous year.

12 Nov 2025

earnings

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800